From Pharmacy Drug Guide
Spiriva®, or the Spiriva® HandiHaler®, was first granted FDA approval in 2004 as a maintenance medication used in the treatment of chronic obstructive pulmonary disease (COPD). The prescription medication may be used alongside a rescue medication to help control COPD symptoms. It does this by relaxing the airways. Spiriva® is indicated for use once daily, working to alleviate symptoms gradually over a 24-hour period.
|Available through||Boehringer Ingelheim Cares Foundation|
|Address||900 Ridgebury Rd., P.O. Box 368, Ridgefield, CT 06877|
|Eligibility||Must be a U.S. resident, meet certain income requirements, meet certain insurance requirements|
|Benefits||Free or discounted medication for up to a year|
|Disclaimer||The information provided by PharmacyDrugGuide is not a substitute for professional medical advice, diagnosis, or treatment. Do not take any action based on the information on this page without consulting a physician.|
Spiriva® is in a class of medications called bronchodilators, and helps open an individual's air passages for easier breathing. The drug is manufactured by Boehringer Ingelheim Pharmaceuticals Inc., and is prescribed for long-term maintenance treatment. Patients taking Spiriva® may experience certain side effects. The most common reaction is dry mouth, but patients may also experience blurry vision and dizziness. In these cases, the drug's manufacturer recommends patients use caution if they plan to operate a vehicle or other machinery.
About Patient Assistance Programs
Spiriva Patient Assistance Programs
Spiriva® is covered by some patient assistance programs, including the Boehringer Ingelheim Cares Foundation, for both patients without insurance coverage and patients who are covered under Medicare beneficiaries. Additional information is available by calling 800-556-8317. All applications to qualify for 2012-13 coverage must meet the following guidelines: applications received between May 16, 2012, and November 15, 2012, will be reviewed by December 2012. Applications received between November 16, 2012, and April 15, 2013, will be examined by May 2013. Applications received between April 16, 2013, and October 15, 2013, will be reviewed by November of 2013. Applications are available to download through the official Boehringer Ingelheim Care Foundation website.
Available patient assistance programs are as follows:
- Patients without insurance may be eligible to receive free Spiriva® for a year if they meet certain qualifications. They must be U.S. residents, have a U.S. physician, meet certain income requirements, and have no prescription drug coverage. Patients for this program are examined case-by-case.
- Patients with Medicare may qualify for assistance paying for Spiriva® if they meet certain eligibility requirements. They must be U.S. residents receiving treatment from U.S. physicians, meet certain income requirements associated with the Federal Poverty Level, and must have at least used three percent of their income on prescription medications over the last year.
Also See: Patient Assistance Programs, Prescription Drugs, Spiriva, Spiriva Coupons, Spiriva Side Effects, Symbicort Patient Assistance Programs, Pulmicort Patient Assistance Programs, Singulair Patient Assistance Programs